{"disease":{"id":"bronchial-neoplasms","name":"bronchial neoplasms"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05907577","title":"Early Detection of Lung Cancer With Machine Learning Based on Routine Clinical Investigations","phase":"","overall_status":"UNKNOWN","enrollment_count":7500,"lead_sponsor_name":"The University Clinic of Pulmonary and Allergic Diseases Golnik","has_results":false},{"nct_id":"NCT06494241","title":"Small/Middle Tier Cities and County Lung Cancer Quality Improvement Project (QIP) Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06831994","title":"Digital Implementation of the German S3 Clinical Practice Guideline for Multimorbidity","phase":"NA","overall_status":"RECRUITING","enrollment_count":660,"lead_sponsor_name":"Universitätsklinikum Hamburg-Eppendorf","has_results":false},{"nct_id":"NCT03037385","title":"Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":590,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT06376084","title":"Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":532,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04697446","title":"External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC","phase":"","overall_status":"UNKNOWN","enrollment_count":279,"lead_sponsor_name":"Blueprint Medicines Corporation","has_results":false},{"nct_id":"NCT04222972","title":"A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":223,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT04862780","title":"(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":177,"lead_sponsor_name":"Blueprint Medicines Corporation","has_results":false},{"nct_id":"NCT05241873","title":"(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":103,"lead_sponsor_name":"Blueprint Medicines Corporation","has_results":false},{"nct_id":"NCT06177925","title":"A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":62,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT06531265","title":"Cryotechnique as a Diagnostic and Therapeutic Tool of Endobronchial Tumors","phase":"NA","overall_status":"COMPLETED","enrollment_count":35,"lead_sponsor_name":"Sohag University","has_results":false},{"nct_id":"NCT02897778","title":"Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Syndax Pharmaceuticals","has_results":false},{"nct_id":"NCT02909452","title":"Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Syndax Pharmaceuticals","has_results":false},{"nct_id":"NCT05153408","title":"(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":20,"lead_sponsor_name":"Blueprint Medicines Corporation","has_results":false},{"nct_id":"NCT03516214","title":"EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"University of Cologne","has_results":false},{"nct_id":"NCT03745859","title":"Evaluation of a New Open Source Virtual Bronchoscope Navigation System","phase":"","overall_status":"TERMINATED","enrollment_count":4,"lead_sponsor_name":"Norwegian University of Science and Technology","has_results":false},{"nct_id":"NCT04644315","title":"A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true}],"total":17},"guidelines":[],"source":"Drug Landscape verified database"}